Manuel Sainz de la Pena, MD
Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1194775817
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $208,140 of the $246,859 with a category attached, or 84.3%. Novo Nordisk accounts for 80.3% of it on its own, with 59 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,146 payments — averaging $215.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$198K
- Bayer$21K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
- Sanofi-aventis U.S. LLC$4K
- Abbott$3K
- Amgen$1K
- plus $12K from 54 others
What the payments were for
- Consulting fees$7,0333%
- Speaking & faculty fees$208,14084%
- Travel & lodging$7,7163%
- Food & beverage$23,81710%
- Education$940%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$86,004
- RYBELSUS$78,089
- Kerendia$20,303
- Tresiba$15,545
- CYCLOSET$6,130
- Xultophy 100/3.6$3,198
- FREESTYLE LIBRE 3$2,580
- Eversense$400
- TEPEZZA$251
- NEXLIZET$250
- NEXLETOL$250
- Korlym$152
- EVENITY$140
- KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT$137
- TZIELD$130
- JARDIANCE$125
- MYCAPSSA$125
- CeQur Simplicity$122
- CRYSVITA$122
- Tymlos$121
How this compares
$246,859 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 312 | $565,045 |
| JardianceEmpagliflozin | 187 | $240,758 |
| RybelsusSemaglutide | 105 | $196,809 |
| FarxigaDapagliflozin Propanediol | 151 | $182,509 |
| TrulicityDulaglutide | 76 | $105,228 |
| Tresiba Flextouch U-200Insulin Degludec | 84 | $80,942 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 63 | $80,000 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 24 | $62,335 |
| Tresiba Flextouch U-100Insulin Degludec | 73 | $46,234 |
| ProliaDenosumab | 26 | $45,880 |
| KerendiaFinerenone | 27 | $41,621 |
| TradjentaLinagliptin | 41 | $36,271 |
| Novolog FlexpenInsulin Aspart | 97 | $34,275 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $33,729 |
| MounjaroTirzepatide | 22 | $32,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog, Levemir | $198,143 | $833,316483 claims |
| Boehringer IngelheimJardiance, Tradjenta | $870 | $277,029228 claims |
| AstraZenecaFarxiga | $692 | $182,509151 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $971 | $141,613109 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,996 | $80,00063 claims |
| AmgenProlia | $1,442 | $45,88026 claims |
| BayerKerendia | $21,253 | $41,62127 claims |
| MerckJanuvia | $95 | $31,79922 claims |
| Radius Health, Inc.Tymlos | $269 | $27,64811 claims |
| AbbVieSynthroid | $383 | $9,666102 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $236 | $6,789678 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Tampa
- Yuvraj KumbkarniTampa$189K
- Andrew HenryTampa$173K
- Bryan McIverTampa$66K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.